Overview Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4 Status: Completed Trial end date: 2015-04-01 Target enrollment: Participant gender: Summary To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia Phase: Phase 3 Details Lead Sponsor: Serenity Pharmaceuticals, Inc.